Autosomal Recessive Spastic Paraplegia Type 66 (SPG66)

Autosomal recessive spastic paraplegia type 66 (SPG66) is a rare, inherited neurological disorder in the large family of hereditary spastic paraplegias (HSPs). Children usually show signs very early in life. The main features are stiffness and weakness in the legs (spasticity and paresis), trouble walking that may progress to loss of walking ability, and signs of peripheral nerve damage (a severe sensorimotor neuropathy). On brain scans, doctors often see underdevelopment (hypoplasia) of the cerebellum and the corpus callosum and sometimes colpocephaly (enlarged back parts of the brain’s fluid spaces). Reflexes in the legs can be absent, and muscles can look thin (amyotrophy). Some children have foot deformities (like pes equinovarus), and mild learning difficulties may be present. SPG66 is caused by harmful variants in the ARSI gene and follows an autosomal recessive inheritance pattern. monarchinitiative.org+3orpha.net+3rarediseases.info.nih.gov+3

Autosomal recessive spastic paraplegia type 66 (SPG66) is a rare, inherited nerve condition that mainly stiffens and weakens the legs (spasticity), starting in infancy or early childhood. Many people also have problems with walking, reduced reflexes or absent reflexes (areflexia), thin leg muscles, and sometimes foot deformity like equinovarus. Brain scans may show a smaller cerebellum or corpus callosum. SPG66 is caused by harmful changes in a gene linked to the arylsulfatase family (ARSI), and it follows autosomal recessive inheritance (a child needs two changed copies, one from each parent). There is no cure yet; treatment focuses on reducing spasticity, protecting joints, keeping mobility, and supporting daily life. Frontiers+3rarediseases.info.nih.gov+3genecards.org+3

The ARSI gene (Arylsulfatase family member I) is associated with SPG66. ARSI belongs to the sulfatase family—enzymes that help break down sulfate-containing molecules; ARSI protein is thought to be locally secreted and Golgi/vesicle-localized in cells. Research resources list SPG66 as an alias for ARSI, supporting the gene–disease link for this subtype of hereditary spastic paraplegia. genecards.org+1

---

Other names

• Hereditary spastic paraplegia type 66

• Autosomal recessive spastic paraplegia-66

• SPG66

• AR-HSP type 66
  These names all refer to the same condition. orpha.net+1

SPG66 happens when a child inherits two non-working copies of the ARSI gene (one from each parent). ARSI encodes a protein in the sulfatase family, enzymes that help process sulfate-containing molecules important for cell membranes and signaling. When ARSI does not work, nerve cells—especially the long upper motor neurons that send signals from the brain to the legs—become vulnerable. Over time, this leads to the spasticity, weakness, and neuropathy seen in SPG66. orpha.net+2biogps.org+2

“Autosomal recessive” means both parents are usually healthy carriers. Each pregnancy has a 25% chance for the child to have SPG66, a 50% chance the child will be a carrier like the parents, and a 25% chance the child will inherit no variant. (This is general information for autosomal recessive conditions.) PMC

---

Types

Although HSPs are often grouped as “pure” (mainly leg spasticity) or “complex” (spasticity plus other neurological features), SPG66 is best described as a complex HSP because it commonly includes severe peripheral neuropathy, absent reflexes, cerebellar and corpus callosum hypoplasia, and sometimes mild intellectual disability, in addition to leg spasticity. Within SPG66, children can still differ in age at onset, speed of progression, and which additional signs are most prominent. orpha.net+2rarediseases.info.nih.gov+2

---

Causes

Important note: The single root cause of SPG66 is pathogenic ARSI variants. The points below explain how this genetic problem leads to the features of the disease and what related mechanisms doctors consider. They are not separate outside causes.

1. ARSI loss of function – two harmful ARSI variants stop the enzyme from working correctly, setting off the disease process. orpha.net

2. Sulfatase pathway disruption – sulfatases regulate sulfate groups on lipids and proteins; disruption alters membrane dynamics in neurons. biogps.org

3. Axonal transport stress – long motor neurons to the legs are especially sensitive to membrane and trafficking problems, leading to length-dependent degeneration. PMC

4. Myelin-axon interaction strain – peripheral nerves may demyelinate or malfunction secondarily, producing sensorimotor neuropathy. PMC

5. Synaptic signaling imbalance – altered membrane components can disturb neurotransmission, increasing spasticity. PMC

6. Developmental brain effects – impaired ARSI function during development can contribute to cerebellar and corpus callosum hypoplasia and colpocephaly. orpha.net+1

7. Motor-unit disuse and weakness – reduced nerve drive over time causes muscle thinning (amyotrophy). orpha.net

8. Peripheral sensory fiber injury – damage to sensory axons worsens balance and foot placement. orpha.net

9. Spinal circuit hyper-excitability – corticospinal tract injury triggers spasticity through reflex pathway changes. PMC

10. Foot and ankle malalignment – chronic tone imbalance shapes the foot into pes equinovarus, further limiting walking. orpha.net

11. Secondary contractures – long-standing spasticity shortens muscles and tendons, reducing range of motion. PMC

12. Deconditioning – reduced mobility leads to lower endurance and fatigue, amplifying disability. PMC

13. Falls and micro-trauma – repeated stumbles cause pain and joint stress, compounding gait limits. PMC

14. Orthopedic changes – hip, knee, and spine alignment may worsen as gait becomes abnormal. PMC

15. Learning/cognitive strain – mild intellectual disability and processing speed issues can arise with the brain changes. rarediseases.info.nih.gov

16. Communication bottlenecks in care – late diagnosis delays supportive therapies; early recognition improves management options. PMC

17. Nutrition and growth impacts – feeding effort or low activity can alter growth/body composition in some children. PMC

18. Psychosocial stress – chronic disability affects mood, participation, and therapy adherence. PMC

19. Respiratory or bulbar strain (occasionally) – severe scoliosis or neuropathy can subtly affect breathing or speech in some complex HSPs. PMC

20. Genetic background (“modifiers”) – other common genetic differences may slightly change severity, even with the same ARSI variants (a general concept in HSP). PMC

---

Common symptoms and signs

1. Stiff, tight legs (spasticity) – muscles resist movement; steps feel scissors-like or jerky. Over time this becomes the main walking problem. PMC

2. Weakness in the legs – especially at the ankles and hips; standing up and climbing stairs get hard. PMC

3. Early walking delay and frequent falls – many children walk later than peers and stumble often. orpha.net

4. Loss or absence of reflexes (areflexia) in legs – due to the severe peripheral neuropathy that accompanies SPG66. orpha.net

5. Muscle thinning (amyotrophy) – legs look slimmer because motor nerves do not fully activate muscles. orpha.net

6. Numbness or tingling – from sensory nerve damage; feet may feel “dead” or “cotton-like.” orpha.net

7. Foot deformity (pes equinovarus) – the foot points downward and inward, making walking and shoe wear difficult. orpha.net

8. Balance problems – standing and turning are unsteady; narrow spaces are scary. orpha.net

9. Fatigue – walking takes much more effort; children tire quickly. Wikipedia

10. Mild learning difficulties – some children need extra help at school. orpha.net

11. Speech or coordination clumsiness – the cerebellum helps with timing and smoothness; when small, movements feel shaky. orpha.net

12. Gait worsening over time – many eventually need a walker or wheelchair, often in childhood or adolescence with SPG66. orpha.net

13. Joint stiffness and contractures – knees and ankles lose range unless stretched and braced. PMC

14. Back curvature (scoliosis) – muscle imbalance can pull the spine out of line. PMC

15. Bladder urgency (sometimes) – spastic pathways can irritate bladder control in some HSPs. Wikipedia

---

Diagnostic tests

A) Physical examination (how the doctor looks and tests at the bedside)

1. Neurological exam for tone, strength, and reflexes – confirms spasticity, measures weakness, and checks if leg reflexes are absent (typical in SPG66 because of neuropathy). This exam anchors the diagnosis. PMC+1

2. Sensory testing (light touch, vibration, pinprick) – looks for sensory loss that points to a sensorimotor neuropathy, common in SPG66. orpha.net

3. Gait analysis in clinic – notes scissoring, toe-walking, foot drop, stride length, and turning; helps plan therapy and braces. PMC

4. Musculoskeletal exam – checks range of motion, contractures, and foot posture (equinovarus) to guide stretching and orthotics. PMC

5. Developmental and cognitive screening – simple tools to spot learning needs early. PMC

B) Manual/functional tests (standardized bedside measures)

6. Modified Ashworth Scale – grades spasticity at each joint to track change over time. PMC

7. 10-Meter Walk Test – measures gait speed with or without devices; sensitive to therapy effects. PMC

8. Timed Up and Go (TUG) – records the time to stand, walk, turn, and sit; reflects overall mobility and fall risk. PMC

9. 6-Minute Walk Test – endurance measure that shows how far a child can walk safely in six minutes. PMC

10. Berg Balance Scale or Pediatric Balance Scale – structured balance scoring that guides physiotherapy targets. PMC

C) Laboratory and pathological tests (to confirm genetics and exclude look-alikes)

11. Targeted or panel-based genetic testing including ARSI – the most direct way to confirm SPG66; modern HSP panels include ARSI. Exome/genome sequencing may be used. orpha.net

12. Vitamin B12, methylmalonic acid, and homocysteine – rules out treatable neuropathies that can mimic HSP. PMC

13. Vitamin E and copper levels – deficiencies may cause spastic ataxia or neuropathy; checking prevents mislabeling. PMC

14. Thyroid tests and basic metabolic panel – screens common metabolic or endocrine issues that worsen weakness and fatigue. PMC

15. Very-long-chain fatty acids (VLCFA) when appropriate – to exclude X-linked adrenoleukodystrophy/adrenomyeloneuropathy, an important HSP mimic. PMC

D) Electrodiagnostic studies (to document nerve involvement)

16. Nerve conduction studies (NCS) – in SPG66 typically show severe sensorimotor neuropathy; helps distinguish from “pure” HSP. orpha.net

17. Electromyography (EMG) – evaluates muscle response and denervation; guides therapy and orthotic planning. PMC

18. Somatosensory evoked potentials (SSEPs) – optional test for central sensory pathway involvement. PMC

E) Imaging tests (to look at brain and spine)

19. Brain MRI – often shows cerebellar and corpus callosum hypoplasia and sometimes colpocephaly in SPG66; these patterns support the diagnosis. orpha.net+1

20. Spine MRI – rules out structural cord problems and documents any cord thinning; helpful in complex HSP work-ups. PMC

Non-Pharmacological Treatments (Therapies & Others)

1. Goal-directed physiotherapy (PT) program
   Description: A structured PT plan combines stretching of hip flexors, hamstrings, and calf muscles; progressive strengthening of hip extensors, knee flexors/extensors, and ankle dorsiflexors; and aerobic work (e.g., treadmill, cycling, water-based training). The focus is safe gait practice, balance, posture, and energy-efficient walking. Sessions often include warm-up, task-specific stepping and turning, and cooldown stretching to prevent contractures. Home exercise is taught to maintain gains. Purpose: ease stiffness, maintain range, strengthen weak muscles, improve walking distance and speed, and reduce falls. Mechanism: repeated stretching reduces hyperactive stretch reflexes and short muscle-tendon units; strengthening and aerobic conditioning improve motor unit recruitment and endurance, helping compensate for corticospinal tract weakness. PMC+2sp-foundation.org+2

2. Daily stretching & contracture prevention routine
   Description: Gentle, sustained stretches (30–60 seconds, repeated sets) for calves, hamstrings, hip flexors, and adductors done twice daily, with caregiver help if needed. Purpose: preserve joint range, prevent equinus and knee/hip contractures that worsen gait. Mechanism: lengthens muscle–tendon units, reduces viscoelastic stiffness, and lowers reflex-mediated resistance to movement over time. Medscape

3. Gait training with body-weight support or aquatic therapy
   Description: Over-ground or treadmill gait practice with harness support, or pool-based walking that unloads joints and allows longer steps with less spasticity. Purpose: safer, longer practice of symmetrical stepping and postural control. Mechanism: repetitive, task-specific locomotor practice drives neuroplasticity and improves central pattern generation; water buoyancy reduces tone and joint load. Medscape

4. Ankle–foot orthoses (AFOs) and custom footwear
   Description: Lightweight AFOs to stabilize the ankle, prevent foot drop, and support knee control; shoes with rocker soles and proper heel counters. Purpose: improve toe clearance, reduce tripping, and optimize push-off. Mechanism: external alignment reduces abnormal plantarflexor moments and leverages ground-reaction forces for safer gait. Medscape

5. Occupational therapy (OT) & adaptive equipment
   Description: OT targets safe transfers, dressing, bathing, and school/work tasks; may recommend grab bars, shower chairs, transfer boards, and writing/typing adaptations. Purpose: protect independence and safety. Mechanism: task simplification and environment changes reduce physical demands and fall risk. Medscape

6. Spasticity education & trigger management
   Description: Teach families how infections, pain, constipation, and stress can worsen tone; build routines for hydration, sleep, and skin care. Purpose: avoid preventable spikes in spasticity. Mechanism: limiting noxious inputs decreases spinal reflex excitability. Medscape

7. Botulinum toxin–assisted therapy (focal spasticity)
   Description: When specific muscles (e.g., gastrocnemius–soleus, tibialis posterior) drive deformity, BoNT-A injections every ~3 months can reduce tone; therapy then focuses on strengthening antagonists and gait retraining. Purpose: relieve focal over-activity to unlock function. Mechanism: presynaptic blockade of acetylcholine at the neuromuscular junction, temporarily weakening overactive muscles. PMC+1

8. Intrathecal baclofen (ITB) evaluation pathway
   Description: For severe, generalized lower-limb spasticity unresponsive to oral drugs, a test dose of intrathecal baclofen is considered. If responsive, a programmable pump may be implanted to deliver baclofen into cerebrospinal fluid at low doses. Purpose: substantial tone reduction with fewer systemic side effects than high-dose oral therapy. Mechanism: GABA-B agonism at the spinal level dampens hyperexcitable stretch reflex arcs. PMC+2SCIRE Professional+2

9. Balance and falls-prevention training
   Description: Cueing strategies, reactive stepping practice, dual-task gait, and home hazard removal (rugs, poor lighting). Purpose: reduce falls and injuries. Mechanism: improves anticipatory and reactive balance responses; safer environment lowers risk. Medscape

10. Care coordination & rare-disease expertise
    Description: Periodic review by a neurologist/rehab team familiar with HSP; referral to centers of excellence and patient groups (e.g., SPF) for education and trials. Purpose: ensure up-to-date, comprehensive care. Mechanism: specialized teams integrate rehab, orthotics, focal treatments, and surgery decisions. rarediseases.info.nih.gov

---

Drug Treatments

Important: No drug is FDA-approved to cure or slow SPG66 itself. The medicines below target spasticity and related symptoms, using dosing guidance from FDA labels where indicated; prescribers individualize doses and monitor side effects.

1. Baclofen (oral)
   Class: GABA-B agonist antispastic. Dosage/Time: Often started low and titrated (e.g., 5–10 mg 3×/day; titrate to effect/tolerability per label products). Purpose: reduce generalized lower-limb spasticity. Mechanism: inhibits excitatory neurotransmission in spinal reflex circuits. Side effects: sleepiness, weakness; abrupt withdrawal can be dangerous (seizures, rebound spasticity). FDA Access Data+2FDA Access Data+2

2. Tizanidine
   Class: central α2-adrenergic agonist. Dosage/Time: start 2 mg; may repeat every 6–8 h up to three doses/day; titrate cautiously. Purpose: reduce spasticity during key activities (short action). Mechanism: presynaptic inhibition of motor neuron firing. Side effects: sedation, dry mouth, hypotension, liver enzyme elevation—monitor. FDA Access Data+1

3. Dantrolene
   Class: direct-acting skeletal muscle relaxant. Dosage: individualized (capsules); warning: hepatotoxicity—use only when indicated and monitor liver function. Purpose: refractory spasticity when benefits outweigh risks. Mechanism: reduces calcium release from sarcoplasmic reticulum, lowering muscle contraction. Side effects: weakness, fatigue, hepatic injury. FDA Access Data

4. OnabotulinumtoxinA (BoNT-A) – focal injections
   Class: neuromuscular blocking biologic. Dosage/Time: adult lower-limb spasticity commonly 300–400 Units divided among ankle/toe flexors; repeat about every 12 weeks. Purpose: targeted tone reduction to improve gait mechanics and brace fitting. Mechanism: blocks acetylcholine release at the neuromuscular junction. Side effects: local weakness, injection-site pain; systemic spread is rare but serious. FDA Access Data

5. OnabotulinumtoxinA (upper-limb patterns)
   Class/Mechanism: as above. Purpose: treat clenched fist, wrist/finger flexor over-activity that interferes with hygiene or mobility aids. Dosing: label-guided muscle-specific dosing with EMG/ultrasound targeting. Adverse effects: similar to #4. FDA Access Data

6. Intrathecal baclofen (programmable pump)
   Class: GABA-B agonist delivered into CSF. Dosage: maintenance often ~50–1000 mcg/day (range wider); dose is titrated by pump programming. Purpose: strong generalized spasticity control when oral therapy fails. Mechanism: spinal inhibition with less systemic sedation. Side effects: overdose (somnolence, respiratory depression), withdrawal if delivery stops—urgent care needed. FDA Access Data+1

7. Diazepam (adjunct for night spasms; clinician-selected)
   Class: benzodiazepine (GABA-A). Purpose: short-term relief of painful spasms, especially nocturnal; used cautiously due to sedation and dependence potential. Mechanism: enhances GABA-A–mediated inhibition. Safety: clinicians consult current label; monitor for drowsiness and falls. Medscape

8. Gabapentin (for neuropathic pain if present)
   Class: α2δ calcium-channel modulator. Purpose: treat neuropathic pain/paresthesia sometimes seen in complicated HSP forms. Mechanism: reduces excitatory neurotransmitter release. Notes: labeling is for epilepsy/PHN; neuropathic pain use follows broader pain guidance; monitor dizziness/somnolence. PMC

9. Pregabalin (for neuropathic pain if present)
   Class: α2δ calcium-channel modulator. Purpose/Mechanism: similar to gabapentin with predictable kinetics; used for neuropathic pain patterns. Safety: dose-adjust in renal impairment; watch for sedation and edema. PMC

10. Analgesic ladder (acetaminophen/NSAID) when pain coexists
    Class: non-opioid analgesics. Purpose: manage musculoskeletal pain from overuse, bracing, or falls; always evaluate GI/renal risks for NSAIDs. Mechanism: COX inhibition (NSAIDs) or central analgesia (acetaminophen). Note: supportive care only; not anti-spastic. Medscape

If you want items 11–20 (e.g., clonazepam in select cases, baclofen ODT/oral solutions for pediatric dosing flexibility, phenol neurolysis under specialist care, etc.), say “continue” and I’ll add them with FDA/source citations.

---

Dietary Molecular Supplements

1. Vitamin D
   Description: Vitamin D supports bone mineralization and neuromuscular function. In spastic disorders with limited mobility, low vitamin D and poor sun exposure are common; deficiency worsens muscle weakness and fracture risk. Typical maintenance dosing ranges from 600–2000 IU/day depending on age, baseline levels, and clinician guidance; treat deficiency per labs. Function/Mechanism: aids calcium absorption, supports muscle and nerve function, and modulates immune and inflammatory pathways—important for safe standing/walking and fall reduction. Note: monitor serum 25-OH D and avoid excess. Office of Dietary Supplements+1

2. Vitamin B12
   Description: B12 keeps nerves healthy and supports myelin and DNA synthesis. Deficiency can cause neuropathy and gait problems, which could compound HSP-related disability. Oral 250–1000 mcg/day or clinician-directed parenteral dosing is used to correct deficiency. Function/Mechanism: cofactor for methylmalonyl-CoA mutase and methionine synthase; supports myelin integrity and neuronal function. Note: supplement when deficient; check levels in anyone with numbness/paresthesia. Office of Dietary Supplements+1

3. Magnesium
   Description: Magnesium is essential for nerve and muscle function and helps regulate excitability. Typical dietary intake is encouraged; supplementation (e.g., 200–400 mg elemental/day) is individualized. Function/Mechanism: cofactor in >300 enzymatic reactions; modulates NMDA receptors and muscle contraction. Note: evidence for preventing idiopathic leg cramps is mixed; supplementation is most useful if dietary intake or serum levels are low. Office of Dietary Supplements+1

4. Creatine monohydrate
   Description: In neuromuscular conditions, creatine can improve muscle strength when combined with resistance training. A common approach is 3–5 g/day (after optional loading) under clinician guidance. Function/Mechanism: increases phosphocreatine stores to regenerate ATP during effort, supporting power and fatigue resistance—useful in weak antigravity muscles. Note: monitor for GI upset and ensure hydration; long-term safety appears acceptable in healthy individuals. PMC

5. Coenzyme Q10 (CoQ10)
   Description: CoQ10 supports mitochondrial electron transport and acts as an antioxidant. Doses vary (e.g., 100–300 mg/day with fat-containing meals). Function/Mechanism: improves electron transfer in complexes I–III and reduces oxidative stress, potentially aiding neuromuscular endurance. Note: human data in HSP are limited; use as an adjunct only. PMC

6. Omega-3 fatty acids (EPA/DHA)
   Description: Fish-oil omega-3s support cardiovascular and anti-inflammatory health. Doses (e.g., 1 g/day combined EPA/DHA) are diet-dependent. Function/Mechanism: modulate eicosanoid pathways and membrane fluidity, which may support general neuromuscular health and recovery from overuse. Note: check for bleeding risk at higher doses. Medscape

7. Folate (if low)
   Description: Folate supports DNA synthesis and methylation; deficiency can worsen anemia and fatigue. Typical supplementation 400–800 mcg/day when needed. Function/Mechanism: one-carbon metabolism supporting neuronal and hematologic health. Note: test and treat deficiency—not a disease-specific therapy. Medscape

8. Calcium (dietary foundation)
   Description: Adequate calcium intake is critical with vitamin D to protect bone when mobility is reduced. Function/Mechanism: mineral for bone; also critical in nerve/muscle signaling. Note: prefer foods; supplement only to reach recommended intake. Office of Dietary Supplements

9. Protein optimization
   Description: Adequate protein (spread through the day) supports muscle maintenance with PT. Function/Mechanism: supplies essential amino acids for muscle repair after therapy sessions. Note: dietitian-guided if renal issues exist. Medscape

10. Multivitamin as a safety net
    Description: A standard once-daily multivitamin helps cover small gaps that can matter when appetite is low or effortful eating limits variety. Function/Mechanism: broad micronutrient coverage to support general health during chronic rehab. Note: avoid megadoses. Medscape

---

Immunity-booster / Regenerative / Stem-cell–type Drugs

1. Intrathecal baclofen (device-delivered “neuro-regulatory” therapy)
   (≈100 words) ITB is not an immune or stem therapy, but it is the most “systems-level” intervention that re-regulates spinal reflex excitability and can transform care in severe spasticity. Dose is continuously infused via a pump and tailored to daily needs, often enabling better PT participation, hygiene, and sleep. Mechanism: GABA-B agonism in the spinal cord reduces hyperreflexia and clonus. Note: requires surgical implantation and specialist follow-up; watch for overdose/withdrawal. FDA Access Data+1

2. Botulinum toxin type A (targeted biologic)
   (≈100 words) BoNT-A is a locally acting biologic that temporarily remodels abnormal muscle activity by weakening over-active muscles while therapy retrains movement. This can be seen as a “functional regenerative window” that lets antagonists strengthen and joints realign. Mechanism: blocks acetylcholine release at neuromuscular junctions. Note: repeat every ~12 weeks; combine with stretching/strengthening for best functional gains. PMC+1

3. Nutritional repletion (Vitamin D/B12) as “immune-supportive” baseline
   (≈100 words) Correcting vitamin D or B12 deficiency does not cure HSP, but it supports immune and neuromuscular health—important when mobility is limited, falls risk is higher, and fatigue or neuropathy co-exists. Mechanisms: Vitamin D modulates immune and neuromuscular function; B12 sustains myelin and nerve signal conduction. Note: test-and-treat strategy, avoiding overdose. Office of Dietary Supplements+1

4. Exercise-based neuroplasticity (as a “regenerative” behavioral medicine)
   (≈100 words) Repeated, task-specific practice (walking, balance, strength) promotes activity-dependent plasticity in surviving pathways. While it doesn’t replace lost long corticospinal axons, it can improve motor patterns, endurance, and life participation over time. Mechanism: use-dependent strengthening of residual circuits and improved muscle oxidative capacity. Note: pair with orthoses and medications for additive benefit. PMC

Experimental stem-cell or disease-modifying therapies for HSP are not established for SPG66 at this time in peer-reviewed clinical guidance. Current care is supportive and symptomatic. Frontiers

---

Surgeries

1. Intrathecal baclofen pump implantation
   Procedure: test dose → surgical placement of a programmable pump with a catheter into intrathecal space; outpatient dose titration follows. Why done: to control severe generalized spasticity when oral drugs fail or cause side-effects, improving comfort, gait training potential, and caregiving. FDA Access Data+1

2. Selective dorsal rhizotomy (SDR) in carefully selected cases
   Procedure: partial sectioning of selected sensory rootlets under electrophysiologic guidance to reduce spastic input. Why done: case series in HSP suggest reduced tone and sometimes gait improvement in selected patients; risks exist and selection is critical. Cureus+1

3. Orthopedic surgery for equinus/equinovarus deformity (e.g., Achilles tendon lengthening)
   Procedure: lengthening tight calf tendon and correcting foot alignment. Why done: to restore plantigrade foot for safer standing/walking when deformity is fixed. Case evidence in HSP shows gait speed and distance improvements in selected patients. PMC+1

Other procedures (e.g., tendon transfers, multilevel corrections) are individualized by orthopedic and neuro-rehab teams; evidence in HSP is evolving. SAGE Journals

---

Preventions

1. Keep a daily home stretch routine to prevent contractures. Medscape

2. Exercise regularly (strength + cardio) within safe limits. Medscape

3. Use orthoses (AFOs) as prescribed to reduce trips and falls. Medscape

4. Manage triggers (constipation, infections, pain) that spike spasticity. Medscape

5. Optimize vitamin D/calcium for bone health. Office of Dietary Supplements

6. Footwear: supportive shoes with good grip and space for AFOs. Medscape

7. Home safety: remove loose rugs, improve lighting, add grab bars. Medscape

8. Regular therapy reviews to update braces and exercises. Medscape

9. Consider focal treatments early when a single muscle group dominates the problem. PMC

10. Vaccinations & general health to avoid illnesses that worsen mobility. Medscape

---

When to see doctors

Seek medical review urgently for sudden increases in stiffness, fever/infection with much worse spasms, new weakness, severe pain, bowel/bladder changes, or after falls with possible injury. If using baclofen (oral or intrathecal), urgent help is needed for signs of overdose (extreme sleepiness, shallow breathing) or withdrawal (severe rebound spasticity, high fever, confusion, seizures). Regular visits are needed for therapy progression, brace checks, and to time BoNT-A repeats or ITB dose adjustments. FDA Access Data+2FDA Access Data+2

---

What to eat” and “what to avoid

Eat more of:

1. Calcium-rich foods (dairy/fortified alternatives) + vitamin D sources (fatty fish, fortified foods). Office of Dietary Supplements

2. High-quality protein with each meal (eggs, fish, legumes, tofu) to support therapy. Medscape

3. Colorful fruits/veg (antioxidants) for general health. Medscape

4. Whole grains for energy and fiber (bowel regularity lowers spasticity triggers). Medscape

5. Hydration (water) to prevent cramps/constipation. Medscape

Limit/avoid:

1. Excess alcohol (falls risk, worsens weakness). Medscape
2. Ultra-processed, high-salt foods (swelling; blood pressure with certain meds like tizanidine). FDA Access Data
   8) High-dose supplements without testing (toxicity risk; e.g., vitamin D mega-doses). Office of Dietary Supplements
   9) Sedating substances together (e.g., benzodiazepines + alcohol). Medscape
   10) Very low-calorie “crash” diets that sap strength needed for PT. Medscape

---

Frequently Asked Questions

1) Is SPG66 the same as other HSPs?
No. SPG66 is one subtype of hereditary spastic paraplegia, linked with the ARSI gene and typically early onset; management principles are shared across HSPs, but gene/phenotype details differ. genecards.org+1

2) How is SPG66 inherited?
It’s autosomal recessive—a child needs two changed copies, one from each parent. Carrier parents have a 25% chance for an affected child in each pregnancy. Genetic counseling is recommended. rarediseases.info.nih.gov

3) What symptoms are common?
Progressive leg stiffness/weakness, gait problems, reduced or absent reflexes, thin leg muscles, sometimes foot deformity and mild learning difficulties; brain MRI can show smaller cerebellum/corpus callosum. rarediseases.info.nih.gov

4) Is there a cure?
Not yet. Care is symptom-focused with rehab, orthoses, focal injections, and sometimes intrathecal baclofen. Frontiers

5) Which therapy matters most?
A consistent physiotherapy program plus home exercise is foundational; add orthoses and focal treatments when needed. PMC

6) When is botulinum toxin helpful?
When a few muscles (e.g., calf invertors/plantarflexors) drive deformity or brace problems; it opens a window for better therapy gains. PMC

7) When is intrathecal baclofen considered?
For severe, generalized spasticity not controlled by oral meds, after a positive test dose and team assessment. PMC

8) Are oral drugs safe?
They can help, but watch sedation and interactions; abrupt baclofen withdrawal is dangerous. Follow label guidance and clinician instructions. FDA Access Data

9) Can surgery improve walking?
In selected cases, Achilles tendon lengthening for fixed equinus and SDR for refractory spasticity can help; decisions are individualized. PMC+1

10) Do supplements help?
They don’t treat SPG66 itself, but vitamin D/B12 repletion, adequate protein, and creatine (with training) can support strength and safety. Test first and avoid megadoses. Office of Dietary Supplements+2Office of Dietary Supplements+2

11) What about stem-cell therapy?
There is no established stem-cell treatment for SPG66 at this time. Enroll only in regulated clinical trials after expert advice. Frontiers

12) How often should therapy be reviewed?
Regularly (e.g., every 3–6 months) to update braces, stretch plans, and consider BoNT-A/ITB if function plateaus. Medscape

13) Are there patient organizations?
Yes—the Spastic Paraplegia Foundation and other rare-disease groups provide education, networking, and trial info. rarediseases.info.nih.gov

14) What tests confirm the diagnosis?
Genetic testing for ARSI/SPG66 in the right clinical picture plus exam, MRI patterns, and sometimes neurophysiology for neuropathy can help the team confirm the subtype. rarediseases.info.nih.gov+1

15) What’s the long-term outlook?
SPG66 is typically early-onset and progressive in the legs, but many people can maintain participation in school/work with tailored rehab, braces, and targeted spasticity treatments. rarediseases.info.nih.gov+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.